The Drugs Controller General of India (DCGI) has been ordered to review the good manufacturing practices (GMP) compliance of the Ranbaxy Laboratories' manufacturing facilities in India after the company faced flak in the US for non-adherence to GMP. Besides, DCGI has also been asked to ascertain the quality, safety and efficacy of drugs manufactured for the domestic market at these facilities.
Ranbaxy USA Inc recently was admitted in the US District Court of Maryland for manufacturing and distribution of certain drugs not in conformity with GMP regulation which is considered as adulterated drugs as per the US law and agreed to pay a fine of $500 million.
Ranbaxy Laboratories, India’s largest pharmaceutical company, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies.
